Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.887
https://www.valueinhealthjournal.com/article/S1098-3015(14)02817-4/fulltext
Title :
Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02817-4&doi=10.1016/j.jval.2014.08.887
First page :
A396
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
404